CHAINON NEUROTROPHIN BIOTECHNOLOGY, INC. (Chainon) is a start-up nutraceutical company focused on the discovery, development and commercialization of orally administered proprietary highly enriched docosahexaenoic acid (DHA; n-3 22:6) - containing phospholipid and alkyl ether phospholipid nutrients, as well as phospholipid drug candidates that target (i) neural membrane and neurotrophin receptors to promote survival of aged basal forebrain cholinergic neurons (BFCNs) in order to prevent and treat age-dependent basal forebrain cholinergic neuron dysfunction related neurodegenerative disorders, (ii) modify fluidity of neural membranes and membrane anti-oxidation by providing brain DHA and ether phospholipid precursors, and (iii) human productive system in order to improve male fertility by enhancing the mobility of human spermatozoa.

The Chainon is a leader in a powerful area called “mechanism-based” discovery of DHA - containing phospholipids and DHA - containing ether phospholipids based brain DHA and anti-oxidant donors, which employs multi-disciplinary science, including chemistry, biochemistry and pharmacology, to identify and better understand the mechanisms by which (i) how DHA can be transported into the brain by phospholipid based transporters and (ii) how the DHA and ether phospholipid donors work on the prevention and treatment of age-dependent neurodegenerative diseases, such as Alzheimer’s disease (AD)/dementia, and Autism.

Using our approach, we are able to design and develop novel DHA phospholipid species based on a variety of key points, in particular how the designed structures of the novel DHA phospholipid and ether phospholipid carriers can be absorbed and distributed properly, then further passing across the blood-brain barrier. Once we have identified the likely mechanisms of action of the target and characterized the properties of the DHA brain donors and ether phospholipid precursors, we use the new methods to extract and purify the phospholipids from new natural materials, as well as semi-synthesize highly pure DHA phospholipid transporters as drug candidates.

“Mechanism-based” discovery of DHA phospholipids and DHA ether phospholipids has been pioneered by Dr. S. Chen, a founder of the Chainon and an expert in the fields of chemistry, biochemistry and pharmacology of phospholipids. Approaches of how to devlop DHA based phospholipid supplements to potential drugs have been established. We believe our approach represents novel methods of making DHA based phospholipid and ether phospholipid supplements and drugs.